目的 觀察中風(fēng)回春片聯(lián)合硫酸氫氯吡格雷片治療急性腦梗死恢復(fù)期的臨床療效。方法 選取2020年3月—2021年8月南陽市第二人民醫(yī)院收治的120例急性腦梗死恢復(fù)期患者，采用隨機數(shù)字表法將所有患者分為對照組和治療組，每組各60例。對照組患者口服硫酸氫氯吡格雷片，75mg/次，1次/d。治療組患者在對照組基礎(chǔ)上口服中風(fēng)回春片，5片/次，3次/d。兩組均連續(xù)治療4周。觀察兩組臨床療效，比較兩組的Barthel指數(shù)（BI）評分、美國國立衛(wèi)生研究院卒中量表（NIHSS）評分、血清炎性因子、神經(jīng)營養(yǎng)指標(biāo)、神經(jīng)損傷指標(biāo)。結(jié)果 治療后，治療組的總有效率（91.67%）明顯高于對照組的總有效率（75.00%），組間比較差異有統(tǒng)計學(xué)意義（P<0.05）。治療后，兩組NIHSS評分下降，BI評分升高（P<0.05），且治療組BI評分高于對照組，NIHSS評分低于對照組（P<0.05）。治療后，兩組血清白細(xì)胞介素-17（IL-17）、白細(xì)胞介素-1β（IL-1β）、超敏C反應(yīng)蛋白（hs-CRP）水平均下降，轉(zhuǎn)化生長因子-β（TGF-β）水平均升高（P<0.05），且治療組血清IL-17、IL-1β、hs-CRP水平低于對照組，TGF-β水平高于對照組（P<0.05）。治療后，兩組血清腦源性神經(jīng)營養(yǎng)因子（BDNF）、胰島素樣生長因子-1（IGF-1）、堿性成纖維細(xì)胞生長因子（bFGF）水平均升高（P<0.05），且治療組血清BDNF、IGF-1、bFGF水平高于對照組（P<0.05）。治療后，兩組血清血清淀粉樣蛋白A（SAA）、心型脂肪酸結(jié)合蛋白（H-FABP）、神經(jīng)損傷指標(biāo)神經(jīng)肽Y（NPY）水平均下降（P<0.05），且治療組血清SAA、H-FABP、NPY水平低于對照組（P<0.05）。結(jié)論 中風(fēng)回春片聯(lián)合硫酸氫氯吡格雷片治療急性腦梗死恢復(fù)期的療效顯著，可提高患者的生活自理能力，促進其神經(jīng)功能恢復(fù)，調(diào)節(jié)血清炎性因子、神經(jīng)營養(yǎng)指標(biāo)、神經(jīng)損傷指標(biāo)水平。

Objective To observe the clinical efficacy of Zhongfeng Huichun Tablets combined with Clopidogrel Bisulfate Tablets in treatment of convalescent acute cerebral infarction. Methods Patients (120 cases) with convalescent acute cerebral infarction in Nanyang Second People’s Hospital from March 2020 to August 2021 were divided into control and treatment groups according to random number table method, and each group had 60 cases. Patients in the control group were po administered with Clopidogrel Bisulfate Tablets, 75 mg/time, once daily. Patients in the treatment group were po administered with Zhongfeng Huichun Tablets on the basis of the control group, 5 tablets/time, three times daily. Patients in two groups were treated for 4 weeks. After treatment, the clinical efficacies were evaluated, and BI scores, NIHSS scores, serum levels of inflammatory factors, neurotrophic indicators, and nerve injury indicators in two groups were compared. Results After treatment, the total effective rate of the treatment group (91.67%) was significantly higher than that of the control group (75.00%), and the difference was statistically significant between the groups (P < 0.05). After treatment, NIHSS scores in two groups were decreased, but BI scores in two groups were increased (P < 0.05), and BI scores of the treatment group were higher than those of the control group, but NIHSS scores of the treatment group were lower than those of the control group (P < 0.05). After treatment, the serum levels of IL-17, IL-1β, and hs-CRP in two groups were decreased, but the serum levels of TGF-β in two groups were increased (P < 0.05). The serum levels of IL-17, IL-1β, and hs-CRP in the treatment group were lower than those in the control group, but the serum levels of TGF-β in the treatment group were higher than those in the control group (P < 0.05). After treatment, the serum levels of SAA, H-FABP, and NPY in two groups were decreased (P< 0.05), and the serum levels of SAA, H-FABP, and NPY in the treatment group were lower than those in the control group (P < 0.05). Conclusion Zhongfeng Huichun Tablets combined with Clopidogrel Bisulfate Tablets has clinical curative effect in treatment of convalescent acute cerebral infarction, can improve the self-care ability of patients, promote the recovery of neurological function, and regulate the serum levels of inflammatory factors, neurotrophic indicators, and nerve injury indicators.

R971

河南省醫(yī)學(xué)科技攻關(guān)計劃聯(lián)合共建立項項目（LHG20201294）